Terry Chrisomalis

Biotechnology DNTH SAN:CA SNY SNY:CA SNYNF Terry Chrisomalis Uncategorized

Dianthus Therapeutics: Go Decision For CIDP Program Warrants Continued Buy Rating

Mar 10, 2026

Biotechnology OCGN Terry Chrisomalis Uncategorized

Ocugen: Downgrading After OCU410 Data Release

Mar 9, 2026

ABBV ABBV:CA ARCT Biotechnology Terry Chrisomalis Uncategorized

Arcturus Therapeutics: Downgrading To “Hold” As CF Program Shifts Population Focus

Mar 6, 2026

ABBV ABBV:CA Biotechnology DAWN IPSEF IPSEY JAZZ LLY LLY:CA Terry Chrisomalis Uncategorized WHWK ZLLY:CA

Day One Biopharmaceuticals: ‘Strong Buy,’ Several 2026 Milestones In Play Plus OJEMDA Growth

Mar 5, 2026

Biotechnology BMY BMYMP CELG.RT NONOF NOVO:CA NVO NVON:CA PRTA RHHBF RHHBY RHHVF ROCH:CA ROG:CA Terry Chrisomalis Uncategorized

Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution

Mar 3, 2026

AZN Biotechnology CGEN GILD GILD:CA Terry Chrisomalis Uncategorized

Compugen: Non-Dilutive Funding For Rilvegostomig Obtained And GS-0321 Advancement

Mar 2, 2026

Biotechnology Terry Chrisomalis TLPPF TLX Uncategorized

Telix Pharmaceuticals: Scope Of Company Beyond Radio Antibody-Drug Conjugate TLX591-Tx

Mar 2, 2026

ALXO Biotechnology Terry Chrisomalis Uncategorized

ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones

Mar 1, 2026

Biotechnology Terry Chrisomalis TGTX Uncategorized

TG Therapeutics: ‘Strong Buy’ On BRIUMVI’s Massive Growth And Possible Expansion

Feb 27, 2026

Biotechnology IRWD TAK Terry Chrisomalis TKPHF Uncategorized

Ironwood Pharmaceuticals: Downgrading On Pipeline Setback And Extended Timeline For Apraglutide

Feb 26, 2026

Next Page »